Search Results

ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.

As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.

For resources on COVID-19 as it applies to the oncology community, please visit ACCC’s continually updated Coronavirus Resource page. ACCC members can also access ACCCExchange, a listserv that allows them to communicate in real time with their colleagues about how the COVID-19 virus is affecting their communities and their patients. As COVID-19 spreads across the U.S., not everyone will get sick. …

Molecular biomarker testing is enabling the delivery of precision oncology treatments, but developing processes and pathways for integrating these complex tests into practice can be challenging. Guidelines are necessary to help oncology stakeholders—not only pathologists, but also oncologists and laboratory personnel—make informed decisions about bringing new biomarker tests into practice and …

ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.